Tb Meningitis

Overview

• Definition: Tuberculous meningitis (TBM) is a severe, life-threatening form of extrapulmonary tuberculosis resulting from Mycobacterium tuberculosis infection of the central nervous system (CNS). It involves inflammation of the meninges and can lead to diffuse cerebral vasculitis, hydrocephalus, and tuberculomas.
• Epidemiology: TBM is the most devastating form of tuberculosis, with high mortality and morbidity, especially in HIV-infected individuals, young children, and immunocompromised patients. It accounts for approximately 5-10% of all extrapulmonary TB cases and 1% of all TB cases globally. Incidence is highest in regions with high TB burden, particularly Sub-Saharan Africa and Southeast Asia.
• Classification: TBM is generally classified by the severity of clinical presentation, often using the British Medical Research Council (BMRC) staging system:
  • Stage I: Patients are fully conscious and alert, without focal neurological deficits, hydrocephalus, or meningeal irritation (Glasgow Coma Scale [GCS] 15).
  • Stage II: Patients have confusion, lethargy, or minor focal neurological deficits (e.g., cranial nerve palsies) but GCS is generally 11-14.
  • Stage III: Patients have severe neurological deficits (e.g., hemiplegia, paraplegia), stupor, coma, or GCS <11.

Pathophysiology

• Mechanism: TBM typically arises from hematogenous dissemination of M. tuberculosis from a primary pulmonary or miliary focus to the CNS. Bacilli are deposited in the brain parenchyma and meninges, forming small subpial or subependymal tuberculomas (Rich foci). Rupture of these Rich foci into the subarachnoid space leads to the release of mycobacteria and host immune components, triggering a pronounced inflammatory reaction. This inflammation results in:
  • Thick, gelatinous exudate accumulating primarily at the base of the brain, causing obstruction of cerebrospinal fluid (CSF) flow and hydrocephalus.
  • Vasculitis (inflammation of blood vessels), particularly in the penetrating arteries of the basal ganglia and internal capsule, leading to ischemic infarction.
  • Cranial nerve dysfunction due to nerve entrapment within the exudate.
  • Direct parenchymal infection forming tuberculomas or diffuse cerebritis.
• Risk Factors:
  • Immunosuppression: HIV infection (especially CD4 count <200 cells/µL), organ transplantation, chronic corticosteroid use, TNF-alpha inhibitors, malignancy.
  • Age: Young children (<5 years), elderly adults.
  • Malnutrition: Micronutrient deficiencies.
  • Close contact: Household or intimate contact with a person with active pulmonary TB.
  • Geographic origin: Origin from or travel to TB-endemic areas.
  • Genetic susceptibility: Certain HLA types.
  • Alcoholism, diabetes, chronic kidney disease.
• Protective Factors:
  • Bacille Calmette-Guérin (BCG) vaccination: Offers partial protection against severe forms of TB, including TBM, in children.
  • Prompt treatment of latent TB infection (LTBI) in high-risk individuals.
  • Effective treatment of active pulmonary TB to prevent dissemination.
  • Good nutritional status.

Clinical Presentation

Signs and Symptoms

Clinical presentation is often insidious, evolving over 2-8 weeks, though acute presentations can occur, especially in children or HIV-infected individuals. - Cardinal Features: - Headache: Persistent, often worsening over days to weeks. - Low-grade fever: Common but may be absent in immunocompromised individuals. - Changes in mental status: Confusion, lethargy, irritability, altered consciousness (progressing from subtle changes to stupor or coma). - Meningismus: Neck stiffness (though can be absent, especially in young children or severe disease). - Cranial nerve palsies: Most commonly involving cranial nerves III, IV, VI, VII. - Early Signs (Prodromal Stage - Stage I BMRC): - Non-specific symptoms lasting 1-2 weeks: malaise, anorexia, headache, low-grade fever, irritability, personality changes, mild nausea/vomiting. - Advanced Signs (Meningitic/Paralytic Stage - Stage II/III BMRC): - Worsening headache, persistent vomiting, increased fever. - Signs of meningeal irritation: stiff neck, positive Kernig's and Brudzinski's signs. - Altered consciousness: somnolence, confusion, stupor, coma. - Focal neurological deficits: cranial nerve palsies (e.g., strabismus, facial asymmetry), hemiparesis, paraparesis, dysphasia. - Seizures. - Hydrocephalus: signs of raised intracranial pressure (ICP) – papilledema, Cushing's triad (bradycardia, hypertension, irregular respiration) in severe cases. - Movement disorders: chorea, dystonia. - Atypical Presentations: - Acute onset mimicking bacterial meningitis. - Absence of fever in immunocompromised patients. - Presentation solely with focal neurological deficits or seizures without overt meningeal signs. - Psychiatric symptoms as initial presentation.

Physical Examination

• Inspection:
  • Level of consciousness (GCS assessment).
  • Evidence of focal neurological deficits (e.g., limb weakness, facial droop, ocular movement abnormalities).
  • Signs of systemic TB (e.g., peripheral lymphadenopathy, skin lesions, signs of miliary TB).
  • Children: signs of hydrocephalus (bulging fontanelle, increased head circumference), emaciation, irritability.
• Palpation:
  • Neck stiffness (nuchal rigidity).
  • Lymphadenopathy.
• Special Tests:
  • Kernig's sign: Pain and spasm of the hamstrings when attempting to extend the knee with the hip flexed to 90 degrees.
  • Brudzinski's sign: Involuntary flexion of the hips and knees upon passive flexion of the neck.
  • Fundoscopic examination: Crucial for detecting papilledema (suggestive of raised ICP) or choroidal tubercles (pathognomonic for miliary TB).

Diagnostic Approach

TBM diagnosis is challenging due to non-specific symptoms, insidious onset, and difficulties in obtaining microbiological confirmation. A high index of suspicion is critical.

History Taking

• Key Questions:
  • Duration and evolution of symptoms (headache, fever, mental status changes).
  • Exposure to active TB (household contact, healthcare worker).
  • Past medical history of TB or LTBI, BCG vaccination.
  • Immunocompromising conditions (HIV, diabetes, organ transplant, immunosuppressant medications).
  • Travel history to TB-endemic regions.
  • Co-morbidities.
• Red Flags:
  • Any neurological symptom (headache, confusion, focal deficit) in a patient from a high-incidence TB area or with known risk factors for TB.
  • Subacute onset of meningitis symptoms.
  • Failure to improve on empirical antibiotic therapy for bacterial meningitis.
  • Evidence of systemic TB.

Laboratory Tests

• First-Line:
  • Blood tests: Complete blood count (variable, may show anemia, leukocytosis or leukopenia), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) (usually elevated, but non-specific), liver and renal function tests (baseline for drug monitoring), electrolytes, HIV serology.
  • Lumbar puncture (LP) and CSF analysis: This is the most critical diagnostic test.
    • Pressure: Often elevated (>200 mm H2O).
    • Appearance: Clear or slightly xanthochromic, may be viscous (cobweb clot formation upon standing).
    • Cell count: Lymphocytic pleocytosis (100-500 cells/µL typically, but can be neutrophilic early in disease or in HIV-coinfection).
    • Protein: Elevated (usually >100 mg/dL, often 200-500 mg/dL).
    • Glucose: Low (CSF:blood glucose ratio <0.5, often <40 mg/dL).
    • Adenosine Deaminase (ADA): Elevated CSF ADA levels (>10 U/L, threshold varies by lab) are highly suggestive of TBM, especially in endemic areas, though not specific.
    • Acid-fast bacilli (AFB) smear: Low sensitivity (10-30%) in CSF. Multiple large-volume CSF samples (6-10 mL) increase yield. Centrifugation of large CSF volumes is crucial.
    • Mycobacterial culture: Gold standard for definitive diagnosis, but slow (up to 6-8 weeks) and sensitivity is variable (30-60%). Critical for drug susceptibility testing.
• Confirmatory:
  • Nucleic Acid Amplification Tests (NAATs):
    • Xpert MTB/RIF (GeneXpert): Endorsed by WHO. Detects M. tuberculosis DNA and rifampicin resistance. Sensitivity in CSF is moderate (50-70%) but higher than AFB smear, with high specificity (95-100%). Performed on fresh CSF.
    • TB-LAMP: Loop-mediated isothermal amplification for M. tuberculosis detection; moderate sensitivity.
  • CSF culture for M. tuberculosis: Confirms diagnosis and provides drug susceptibility.
  • Pathological examination: Biopsy of extrapulmonary lesions (meningeal, brain, lymph node) showing granulomas with caseating necrosis and AFB. (Rarely performed for TBM diagnosis directly).
• Monitoring:
  • Repeat CSF analysis if clinical course is atypical or to assess response (not routinely recommended to guide treatment duration).
  • Therapeutic drug monitoring for anti-TB drugs in specific cases (e.g., suspicion of malabsorption or treatment failure).

Imaging

• Recommended:
  • Magnetic Resonance Imaging (MRI) of the brain with contrast: Superior to CT for TBM.
    • Typical findings: Basal meningeal enhancement, hydrocephalus (communicating or obstructive), infarcts (especially in basal ganglia, internal capsule), tuberculomas (ring-enhancing lesions), edema.
    • MR spectroscopy: May show lipid peaks in tuberculomas.
  • Computed Tomography (CT) scan of the brain with contrast: More readily available but less sensitive than MRI.
    • Typical findings: Basal cistern enhancement, hydrocephalus, infarcts, tuberculomas (hypo- or iso-dense lesions with ring enhancement).
• Advanced:
  • Diffusion-weighted imaging (DWI): To detect acute ischemic infarcts.
  • MR angiography: To assess vasculitis and arterial narrowing.
  • Spinal MRI: If spinal symptoms or radiculopathy suggestive of spinal involvement (e.g., spinal tuberculoma, arachnoiditis).

Management

Management of TBM is complex, requiring prompt initiation of antituberculosis drugs, corticosteroids, and often management of complications.

Acute Management

• Immediate:
  • Start empiric anti-TB therapy immediately upon suspicion: Do not wait for microbiological confirmation. Delay in treatment is associated with worse outcomes.
  • Corticosteroids: Dexamethasone is crucial for reducing inflammation, cerebral edema, and mortality.
  • Management of raised ICP: Head elevation, careful fluid restriction, mannitol or hypertonic saline if herniation is suspected.
• Stabilization:
  • Airway, Breathing, Circulation (ABC) assessment and support.
  • Fluid and electrolyte management: Hyponatremia (due to SIADH or adrenal insufficiency) is common and requires careful management.
  • Seizure control: Antiepileptic drugs (e.g., lorazepam for acute seizures, then levetiracetam or phenytoin).
• Emergency:
  • Neurosurgical intervention: For severe hydrocephalus (ventriculostomy, ventriculoperitoneal [VP] shunt insertion) or decompression of large, symptomatic tuberculomas causing mass effect. Performed in coordination with medical team.

Chronic Management

• Pharmacological:
  • Antituberculosis Drugs:
    • Regimen: Current WHO guidelines recommend an intensive phase of 2 months followed by a continuation phase of 7-10 months, or 9-12 months for rifampicin-sensitive TBM (total 9-12 months).
    • Adults (WHO recommended regimen for TBM):
      • Intensive Phase (2 months): Isoniazid (INH), Rifampicin (RIF), Pyrazinamide (PZA), Ethambutol (EMB).
      • Continuation Phase (7-10 months): INH, RIF.
    • Dosages (adjusted for TBM due to CNS penetration):
      • Isoniazid (INH): 5-10 mg/kg/day (max 300 mg/day). Some experts recommend 10-15 mg/kg for TBM.
      • Rifampicin (RIF): 10-15 mg/kg/day (max 600 mg/day).
      • Pyrazinamide (PZA): 20-30 mg/kg/day (max 2 g/day).
      • Ethambutol (EMB): 15-25 mg/kg/day (max 1.2 g/day).
      • Levofloxacin/Moxifloxacin: May be added, especially in areas with high drug resistance or severe disease, given their good CSF penetration.
    • Drug-resistant TBM: Based on drug susceptibility testing (DST), consult with an expert in TB. May involve fluoroquinolones, injectables (amikacin, capreomycin), prothionamide, cycloserine, bedaquiline, delamanid. Treatment duration extended to 18-24 months.
  • Corticosteroids: Dexamethasone is crucial for reducing mortality in TBM.
    • Regimen (Adults):
      • Stage I: 0.3 mg/kg/day for 1 week, then tapered over 3-4 weeks.
      • Stage II/III: 0.4 mg/kg/day for 1 week, then 0.3 mg/kg/day for 1 week, then 0.2 mg/kg/day for 1 week, then 0.1 mg/kg/day for 1 week, followed by gradual taper over 3-4 weeks (total 6-8 weeks).
    • Route: Initially IV, then oral once clinical stability is achieved.
  • Adjunctive agents:
    • Pyridoxine (Vitamin B6): 25-50 mg/day to prevent INH-induced peripheral neuropathy.
    • Antiepileptics: For seizure control.
• Non-pharmacological:
  • Nutritional support: Ensure adequate caloric intake.
  • Rehabilitation: Physical, occupational, and speech therapy for neurological deficits.
  • Psychological support: For patients and families dealing with chronic illness and disability.
• Monitoring:
  • Clinical monitoring: Neurological status, signs of raised ICP, adverse drug reactions.
  • Biochemical monitoring: Liver function tests (ALT, AST, bilirubin), renal function, electrolytes (Na+), complete blood counts (for marrow suppression by RIF).
  • Ophthalmologic monitoring: Baseline and periodic for visual acuity and color vision (for EMB).
  • Audiometry: Baseline and periodic for ototoxicity (if aminoglycosides used for MDR-TB).
  • Drug susceptibility testing (DST): Where available, for all confirmed cases.

Treatment Algorithms

• First-Line:
  1. High clinical suspicion of TBM (clinical criteria + CSF suggestive + imaging suggestive).
  2. Start fixed-dose combination (FDC) anti-TB drugs: INH, RIF, PZA, EMB at TBM-specific doses (or single drugs if FDC not available).
  3. Start Dexamethasone (IV initially, then oral).
  4. HIV-positive patients: Start antiretroviral therapy (ART) 2-8 weeks AFTER initiating TBM treatment, to avoid immune reconstitution inflammatory syndrome (IRIS) in the CNS.
  5. Neurosurgical consultation for hydrocephalus.
• Second-Line:
  • If drug resistance is suspected (e.g., no clinical improvement, known contact with drug-resistant TB, or previous treatment failure):
    • Add a fluoroquinolone (levofloxacin or moxifloxacin).
    • Obtain rapid molecular tests (e.g., Xpert MTB/RIF Ultra, line probe assay) directly from CSF if possible, or from another site (e.g., sputum) if available.
    • Await full DST results to guide regimen modification.
• Refractory Cases:
  • Non-response to treatment (persistent fever, worsening neurological status, persistent inflammatory CSF):
    • Re-evaluate drug adherence and appropriate dosing.
    • Rule out drug resistance via repeat DST.
    • Consider alternative diagnoses or co-infections.
    • Review for complications (e.g., increasing hydrocephalus, new infarcts, intracranial tuberculoma growth).
    • May require extended duration of initial therapy or introduction of second-line agents.
    • Consider therapeutic drug monitoring to ensure adequate CNS drug levels.

Complications

• Common:
  • Hydrocephalus: Communicating or obstructive, requiring VP shunting.
  • Cranial nerve palsies: Most commonly oculomotor (III, IV, VI) and facial (VII) nerves.
  • Cerebral infarction: Due to vasculitis, leading to focal neurological deficits (hemiparesis, dysphasia).
  • Seizures: Focal or generalized.
  • Hyponatremia: Due to SIADH or adrenal insufficiency.
• Serious:
  • Brain herniation: Due to severe raised ICP.
  • Drug-induced hepatotoxicity: From anti-TB drugs.
  • Spinal arachnoiditis: Can lead to paraplegia.
  • Optic neuritis/blindness: Severe vision loss secondary to inflammation or direct involvement.
  • Adrenal insufficiency: From chronic steroid use or rarely direct adrenal involvement.
• Long-term:
  • Cognitive impairment: Memory deficits, executive dysfunction.
  • Neuroendocrine disturbances: Hypopituitarism (especially in children), diabetes insipidus.
  • Epilepsy.
  • Motor deficits: Spasticity, weakness.
  • Hydrocephalus requiring permanent shunt.
  • Psychiatric sequelae: Depression, anxiety.

Prognosis

• Factors:
  • Stage of disease at presentation: Stage I has best prognosis, Stage III has highest mortality and morbidity.
  • Age: Young children and elderly have worse outcomes.
  • HIV co-infection: Associated with higher mortality, especially with low CD4 counts.
  • Drug resistance: Significantly worsens prognosis.
  • Delay in diagnosis and treatment: Major determinant of poor outcome.
  • Presence of complications: Hydrocephalus, infarcts, seizures.
• Survival: Mortality rates vary geographically and by population, but are high.
  • Overall mortality: 15-40% in immunocompetent adults.
  • HIV co-infection: Up to 50-70%.
  • Children: Up to 30-50%.
• Quality of Life:
  • Significant proportion of survivors (20-50%) experience permanent neurological sequelae impacting quality of life, including cognitive deficits, motor impairments, epilepsy, and visual/hearing loss.
  • Children often have more severe and long-lasting developmental and neurological impairments.

Prevention

• Primary:
  • BCG vaccination: Recommended for infants in high-burden countries to protect against severe forms of TB, including TBM.
  • Early diagnosis and effective treatment of pulmonary TB: To prevent transmission and dissemination.
  • Contact investigation: Identify and treat latent TB infection (LTBI) in close contacts of active TB cases.
  • Infection control measures: In healthcare settings and crowded environments.
• Secondary:
  • Screening and treatment of LTBI: In high-risk groups (HIV-infected individuals, immunosuppressed patients, close contacts of active TB cases).
  • Prompt investigation of meningitis in high-risk individuals: Early diagnosis and initiation of treatment.
• Tertiary:
  • Aggressive management of complications: Hydrocephalus, seizures, neurological deficits.
  • Multidisciplinary rehabilitation: To maximize functional recovery and improve quality of life.
  • Long-term follow-up: To monitor for recurrence or new complications.

Special Populations

• Pediatric:
  • Often present with non-specific symptoms (irritability, poor feeding, developmental regression). Hydrocephalus is very common.
  • Dosages of anti-TB drugs are weight-based. Dexamethasone is also crucial.
  • High risk of severe neurological sequelae and developmental delay.
  • Intraventricular streptokinase has been explored for hydrocephalus but not routinely recommended.
• Geriatric:
  • Atypical presentation is common, often subtle and insidious or presenting with only confusion or lethargy.
  • Increased risk of drug toxicity, polypharmacy interactions, and falls.
  • Higher mortality rates.
• Pregnancy:
  • TBM in pregnancy is rare but serious.
  • Standard anti-TB regimen is generally safe (INH, RIF, EMB, PZA). Streptomycin is contraindicated due to ototoxicity to the fetus.
  • Dexamethasone should be used as indicated.
  • Close monitoring for adverse effects and fetal well-being is essential.
• Comorbidities:
  • HIV co-infection:
    • Higher risk of TBM, often with atypical CSF findings (more neutrophils, lower glucose, less pleocytosis).
    • Higher mortality. Rifampicin interacts significantly with many antiretroviral drugs, requiring careful selection and dose adjustments.
    • Timing of ART initiation: Crucial to balance benefits of ART with risk of TB-IRIS. Current WHO guidelines recommend starting ART 2-8 weeks after initiating anti-TBM treatment in HIV-infected patients, regardless of CD4 count.
  • Diabetes Mellitus: Increased risk of TB, including TBM. Requires careful glucose control.
  • Chronic kidney disease: Anti-TB drug dosages (EMB, PZA, INH) require adjustment to prevent toxicity.

Clinical Pearls

• Diagnostic:
  • Think TBM: In any patient with subacute meningitis, particularly in endemic areas or with risk factors, even if CSF shows predominantly neutrophils.
  • Large volume CSF for NAATs/culture: Always send 6-10 mL of CSF for mycobacteriology to increase yield.
  • Repeat LP: If initial CSF is non-diagnostic and suspicion remains high.
  • Early imaging: MRI with contrast is preferred when TBM is suspected.
  • CSF ADA: A useful adjunct, especially in resource-limited settings, but confirm local cut-off values.
• Treatment:
  • Start early: Do not delay treatment awaiting confirmation.
  • Steroids save lives: Dexamethasone is essential in all TBM stages.
  • High doses for CNS penetration: Consider higher ends of the dose range for INH and RIF to optimize CNS penetration.
  • Drug interactions: Be vigilant, especially with RIF and ART for HIV-co-infected patients.
  • Monitor electrolytes: Hyponatremia is common.
• Pitfalls:
  • Misdiagnosis as viral meningitis or partially treated bacterial meningitis: Leading to delayed treatment.
  • Underdosing anti-TB drugs: Especially in early stage where CNS penetration might be crucial.
  • Failure to use corticosteroids: Significantly increases mortality.
  • Ignoring signs of complications: Such as hydrocephalus or drug toxicity.
  • Starting ART too early in HIV-co-infected patients: Increasing the risk of TB-IRIS.

Recent Updates

• Guidelines:
  • WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment. 2020 and 2022 updates emphasize updated drug regimens for drug-resistant TB and timing of ART in HIV-TB co-infection.
  • New WHO recommendations on longer duration of continuation phase (7-10 months) for Category 1 regimen for TBM.
• Evidence:
  • Emerging evidence supports higher dosing of rifampicin (e.g., 15 mg/kg body weight) for adult TBM to improve CNS penetration and outcomes, though this is not yet universally adopted into mainstream guidelines.
  • Research into host-directed therapies (e.g., aspirin) as adjuncts is ongoing but not yet standard of care.
  • Development of next-generation molecular diagnostic tests with improved sensitivity directly from CSF.
• Controversies:
  • Optimal duration of anti-TB treatment for TBM (9-12 months vs. longer).
  • Optimal dose of rifampicin in TBM for better CNS penetration.
  • Role of add-on therapy like high-dose aspirin.
  • Precise timing of ART initiation in HIV-TBM co-infection, balancing IRIS risk vs. ART benefit.

Key References

• Guidelines:
  • World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: Treatment – drug-resistant TB treatment. 2020 update.
  • World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: Treatment – tuberculosis in children and adolescents. 2022 update.
  • Thwaites GE, van Toorn R, Schoeman J. Tuberculous meningitis: more questions than answers. Lancet Neurol. 2013;12(10):999-1010.
• Studies:
  • Marais S, et al. Dexamethasone and adjunctive therapy for tuberculous meningitis. Cochrane Database Syst Rev. 2016;9:CD004402. (Meta-analysis supporting corticosteroid use).
  • Heemskerk AD, et al. Rifampicin-associated adverse events and drug-drug interactions in HIV/TB co-infected patients receiving a 4-drug, 24-month high-dose rifampicin regimen for tuberculous meningitis: an open-label, non-randomised, dose-escalation trial. Lancet Infect Dis. 2022;22(9):1314-1324.
• Reviews:
  • Al-Hajoj S A, et al. Tuberculous meningitis: Diagnosis, treatment, and challenges. J Med Microbiol. 2020;69(11):1456-1466.
  • Marx GE, Bassin BR. Tuberculous Meningitis: Review of Clinical Presentation, Diagnosis, and Treatment. J Neurosci Rural Pract. 2015;6(1):15-22.

---

Disclaimer: This information is provided for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Treatment decisions should always be made by a healthcare professional in light of the patient's specific circumstances and prevailing clinical guidelines.